Çiğdem Mermutluoğlu

Dr. Çiğdem Mermutluoğlu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
ÇMÇiğdem Mermutluoğlu
Çiğdem Mermutluoğlu
RDRecep Dursun
Recep Dursun
FAFesih Aktar
Fesih Aktar
SDSaim Dayan
Saim Dayan
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen
RTRecep Tekin
Recep Tekin
Introduction: This study aims to research the effects of hematological and inflammatory parameters on the prognosis of COVID-19 disease and hospitalization duration. Methodology: One hundred and eighty-six patients with COVID-19 and a control group consisting of 187 healthy individuals were included in the study. Hematological variables and inflammatory parameters of the patients were recorded on the first and the fifth days of hospitalization. Results: White blood cell count, lymphocyte count, and platelet count were statistically lower, and mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) levels were higher in the patient group compared to the control group. It was observed that the neutrophil count and MPV level were lower, and the platelet count and ferritin level were statistically higher on the fifth day of follow-up compared to the admission day. In contrast, there was a significantly positive correlation between the duration of hospitalization and the fifth day D-dimer (r = 0.546, p < 0.001) and ferritin (r = 0.568, p < 0.001); in addition, there was a negative correlation between the duration of hospitalization and admission day lymphocyte count and the fifth-day lymphocyte count. Conclusions: Increased levels of ferritin and D-dimer, and decreased count of lymphocytes are among the important factors affecting the duration of hospitalization for COVID-19 patients. Furthermore, we think that neutrophil count and MPV levels are low, and platelet count and ferritin levels are high during the disease. Therefore, these parameters can be used as prognostic indicators of the disease.


23 June 2023 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
YYYesim Yildiz
Yesim Yildiz
HOHasan Ozger
Hasan Ozger
AAAli Acar
Ali Acar
ASAysegul Seremet-Keskin
Aysegul Seremet-Keskin
UBUmut Devrim Binay
Umut Devrim Binay
ESEsin Senol
Esin Senol
Objective: We aimed to investigate the vaccination status and the risk factors for the intensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpatients, divided into two groups as ‘fully’ and ‘partially’ vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mellitus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the predominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group’s need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vaccinated were associated with the need for ICU support. Therefore, all countries should continuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection. Keywords: COVID-19 vaccine, intensive care unit, risk factor, SARS-CoV-2 infection, vaccine breakthrough infections, variant of concerns

1 August 2023 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
TÇTUBA DAMAR ÇAKIRCA
TUBA DAMAR ÇAKIRCA
TYTansu Yamazhan
Tansu Yamazhan
EYEsra Yüksekkaya
Esra Yüksekkaya
FAFethiye AKGÜL
Fethiye AKGÜL
BKBehice Kurtaran
Behice Kurtaran
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen

1 January 2022
Verified
Journal Article
Closed access
ÇMÇiğdem Mermutluoğlu
Çiğdem Mermutluoğlu
RTR. Tekin
R. Tekin
RTR. C. Tekin
R. C. Tekin
STS. Tekin
S. Tekin
RER. e. canpolat Erkan
R. e. canpolat Erkan
SDS. Dayan
S. Dayan

31 March 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
MÇMustafa K Çelen
Mustafa K Çelen
BŞBuket Ertürk Şengel
Buket Ertürk Şengel
SKSafak Kaya
Safak Kaya
NDNeşe Demirtürk
Neşe Demirtürk
AAAlpay Azap
Alpay Azap
ÇMÇiğdem Mermutluoğlu
Çiğdem Mermutluoğlu
Introduction: The aim of this national, multicenter, cross-sectional, retrospective chart review study was to determine the proportion of patients in Turkey who received hepatitis C virus (HCV) treatment after receiving positive anti-HCV results during HCV screening. Methodology: Data related to patients’ demographics, laboratory results, time interval from obtaining a positive anti-HCV result to treatment initiation, specialty of the physician requesting anti-HCV screening, and type of hospital were analyzed. Results: Among 1,000 patients who received a positive anti-HCV result, 50.3% were male and 78.5% were screened for HCV-RNA. Among HCV-RNA screened patients, 54.8% (n = 430) had a positive result. Among patients who tested positive for HCV-RNA, 72.8% received HCV treatment in line with their positive anti-HCV results. The median time from obtaining a positive anti-HCV result to initiation of HCV treatment was 91.0 days (interquartile range 42.0 to 178.5). Non-surgical branches requested HCV-RNA testing more frequently than surgical branches (p < 0.001). The rate of access to HCV treatment was higher among patients screened in university hospitals than among patients screened in training and research hospitals (p < 0.001). Conclusions: Our results indicate a higher rate of treatment initiation among patients with HCV infection than is described in the published literature. Furthermore, the time from screening to treatment initiation was considerably shorter compared with other international studies. However, since HCV-RNA testing was not requested in a significant portion of patients with a positive anti-HCV test result, there might be a large patient population with HCV who do not receive treatment.